-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Daejeon, South Korea, October 20, 2021/PRNewswire/ - On September 2, 2021, GenKOre published a scientific paper in the online version (IF 54.
gene scissor technology
Only by delivering the genetic load to the necessary location in the patient can efficient gene therapy be performed, and the best way to achieve this is to use adeno-associated virus (AAV) as a vector
The gene size of the "CRISPR/Cas12f-GE" system developed by GenKOre is 1/3 of that of Cas9, so it becomes the ideal load for AAV delivery
The ultra-compact CRISPR system Cas12f-GE reveals its value as a therapeutic drug, and can be widely used to develop therapies for patients who suffer from lifelong diseases for a long time due to lack of fundamental therapies
GenKOre, which successfully developed this new technology, is a spin-off company of Korea Research Institute of Bioscience & Biotechnology (KRIBB), a research institution funded by the Korean government
GenKOre CEO Dr.
With the successful development of CRISPR/Cas12f-GE, GenKOre plans to accelerate the development of gene therapy and new products through its unique gene scissors technology, and cooperate with other companies to strive to become a market leader in the field of gene therapy and new plant biotechnology
To learn more about GenKOre's papers published on the online version of "Nature Biotechnology", please visit: https://
Please visit GenKOre's website:.
Source: GenKOre